Back to School: How biopharma can reboot drug development. Access exclusive analysis here

KPT-330: Phase I data

Data from 23 patients in the dose-escalation portion of an open-label, international Phase I trial showed that 3-30 mg/m 2 doses

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE